

Mary Perry RD CCRC  
5/2/07

**Curriculum Vitae**  
**MARY L. PERRY, RD, CCRC**

**Business Address:**

National Clinical Research, Inc.  
2809 Emerywood Parkway  
Suite 140  
Richmond, VA 23294  
(804) 672-2133 ext. 21

**EDUCATION:**

1983 - 1988                      B.S., Foods and Nutrition, Magna Cum Laude  
Virginia State University  
Petersburg, VA

**PROFESSIONAL EXPERIENCE:**

May 2006 – present              Certified Clinical Research Coordinator  
National Clinical Research, Inc.  
Richmond, VA

Dec. 2002 – May 2006            CRC in Training  
National Clinical Research, Inc.  
Richmond, VA

Jun. 2000 - present                Dietitian  
National Clinical Research, Inc.  
Richmond, VA

1992 – Jan 2004                    Nutritionist/Fitness Trainer  
Chester Family YMCA  
Chester, VA

Oct. 2000 – Feb 2001            Nutritionist  
Gateway Homes of Richmond  
Chesterfield, VA

1999 – Oct. 2000                   Instructor for the Behavioral Center  
Hallmark of Westend  
Richmond, VA

1998 – Jun 2000                    Dietitian  
American Family Fitness Centers  
Richmond, VA

1999 - Apr. 2000                   Instructor for the Dietetic Internship Program  
Virginia State University  
Petersburg, VA

1995 - 1999                          Nutritionist  
Virginia Cardiovascular Risk Reduction Program  
Hanover Health District  
Ashland, VA

1994 - 1995                          Dietetic Internship  
Medical College of Virginia Hospitals  
Richmond, VA

**PROFESSIONAL AFFILIATIONS:**

American Dietetic Association  
Virginia Dietetic Association  
Richmond Dietetic Association

**CERTIFICATIONS:**

Certified Clinical Research Coordinator (5/06 – present)

**CLINICAL RESEARCH EXPERIENCE**

Study Coordinator

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter study to assess the efficacy and safety of long-term administration of rimonabant in the prevention of Type 2 Diabetes in patients with prediabetic status (i.e., Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or both), Sanofi-Aventis (Protocol No. EFC5107), Sep06.

A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Obese Patients, Arena/ICON (Protocol APD356-009), Sep06.

A Phase IIb/III Randomized, Placebo-controlled, Clinical Trial to Study the Safety and Efficacy of MK-0364 in Obese Patients and in Overweight Patients with Obesity-Related Co-morbidities, Merck (Protocol 037), Oct06.

A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Safety and Efficacy of Orally Administered MD-0727 in Patients with Primary Hypercholesterolemia, Microbia/Medpace (Protocol MCP-104-201), Nov06.

A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 IN The Treatment Of Obese Subjects, Pfizer/ICON (Protocol A5351025), Nov06.

CRC in Training

A Study to Assess the Safety and Efficacy of L-000899055 in Obese Patients, Merck (Protocol 006), Jul04.

A Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study To Assess The Time To Onset, Safety, And Toleration Of Differing Doses And Combinations Of Immediate Release And Modified Release Formulations Of UK369,003 In Adult Male Subjects With Erectile Dysfunction , Pfizer (Protocol A3711029 – 1038), Mar05.

A randomized, double-blind, placebo-controlled, parallel-group, fixed dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve patients with type 2 diabetes (SERENADE), Sanofi~Synthelabo (Protocol EFC5825), Mar05.

Atherosclerosis Underlying Development Assessed By Intima-Media Thickness In Patients On Rimonabant (AUDITOR), Sanofi~Synthelabo (Protocol EFC5828), May05.

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of L-000328495 in Obese Patients, Merck (Protocol 001), Jun05.

An 18-Month Study to Assess the Efficacy, Safety, and Tolerability of L-000899055 in Obese Patients, Merck (Protocol 020), Aug05.

